Spruce Biosciences (SPRB) Stock: Buy, Sell, or Hold?
SPRB - Spruce Biosciences, Inc. Common Stock
$45.15
-0.85 (-1.85%)
▼
5d:
+13.87%
30d:
-7.89%
90d:
+7.53%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 09, 2026
15d
Get Alerted When SPRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SPRB shows positive signals but monitor for confirmation. Market pricing in 8.6% decline. Moderate conviction.
💡 BUY OPPORTUNITY: SPRB shows positive signals but monitor for confirmation. Market pricing in 8.6% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$82.95
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$51.51
12.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SPRB is currently trading at $45.15, which is considered fair relative to its 30-day fair value range of $41.69 to $50.86. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.1) compared to its historical average (11.9). Remarkably, the market is currently pricing in an annual earnings decline of 8.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SPRB is showing sideways momentum. The price is approaching resistance at $46.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SPRB scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $148.00 (+227.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SPRB is showing sideways momentum. The price is approaching resistance at $46.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SPRB scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $148.00 (+227.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$41.69 -
$50.86
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 227.8% below Wall St target ($148.00)
- BULLISH: Bottoming setup score 66/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$41.69 -
$50.86
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$38.06
Resistance Level
$46.25
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.08
Wall Street Target
$148.00
(+227.8%)
Revenue Growth (YoY)
-75.9%
Valuation Discount vs History
-8.6% cheaper
PE vs Historical
9.1 vs 11.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.6%
(market-implied from PE analysis)
1-Year Target
$41.27
(-9%)
2-Year Target
$37.72
(-17%)
3-Year Target
$34.47
(-24%)
3-Yr Target (if PE normalizes)
(PE: 9→12)
$45.20
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.1 to 11.9
Stabilization Target:
$59.20
(+31.1%)
PE Expansion Potential:
+31.1%
Share & Embed Analysis
Last updated: October 24, 2026 1:14 PM ET
Data refreshes hourly during market hours. Next update: 2:14 PM
Data refreshes hourly during market hours. Next update: 2:14 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$106 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 58 HOLD |
